Thursday, July 18, 2013 8:31:24 AM
Well lookie here, NNVC has disrespected resistance level! And a higher high on nearly 3 times the average volume!
Two events that precede the coming series of parallel events beginning this year:
->BASi for Toxicology and Safety Studies - agreement signed Nov 12, 2012; NNVC ANTICIPATES that it will need very large quantities of the drug candidate for these “tox package” studies.
->NNVC announced it has retained the services of Mr. Phil Mader and his firm, MPH Engineering, LLC (“MPH”), to help with the overall project management and design engineering of its laboratory and cGMP pilot production facility
According to your 6 month modeling, if the cGMP facility is physically completed by or before Sep - Oct 2013, it will be sometime between October 2013 and April 2014 when they start production of the test batches.
Events running in parallel for a year - beginning sometime between Sep - Oct 2013 when cGMP facility is physically complete:
-cGMP plant/facilities complete sometime in or before October 2013; transition to full production of TEST BATCHES begins sometime before Apr 2014;
-Human trials begin outside the U.S. (Australia) sometime during first half of 2014. Since it is outside the U.S. no FDA approval is necessary
-Sometime close to/before April 2014 FDA certifies cGMP plant/facilities; production test batches have begun; test batches can be employed in Human trials Australia as well as for Tox studies.
Puffer, you've said, "As a near term catalyst you've got potential Dengue approval for orphan status both here and in Europe. That should be forthcoming, possibly within a few weeks (due within 3 mos of 10 Jun in the U.S.). Beyond that I would encourage people to look at the big picture. We could be in or very close to human trials 1 yr hence. Phase I/IIa should only take about 6 weeks... positive results there and $1.00 will be a distant memory. I would also expect higher prices as we approach those trials."
I must say I like the big picture. Nanopatent recently brought to our attention Nanowerk news -- Cancer nanotechnology: Nanoparticles with protein 'passports' evade immune system. Others have alluded to a similar mechanism/passport employed by NNVC in the "human-like cells" or nanomicelles.
Download the "soaring to new highs" video --
Two events that precede the coming series of parallel events beginning this year:
->BASi for Toxicology and Safety Studies - agreement signed Nov 12, 2012; NNVC ANTICIPATES that it will need very large quantities of the drug candidate for these “tox package” studies.
->NNVC announced it has retained the services of Mr. Phil Mader and his firm, MPH Engineering, LLC (“MPH”), to help with the overall project management and design engineering of its laboratory and cGMP pilot production facility
According to your 6 month modeling, if the cGMP facility is physically completed by or before Sep - Oct 2013, it will be sometime between October 2013 and April 2014 when they start production of the test batches.
Events running in parallel for a year - beginning sometime between Sep - Oct 2013 when cGMP facility is physically complete:
-cGMP plant/facilities complete sometime in or before October 2013; transition to full production of TEST BATCHES begins sometime before Apr 2014;
-Human trials begin outside the U.S. (Australia) sometime during first half of 2014. Since it is outside the U.S. no FDA approval is necessary
-Sometime close to/before April 2014 FDA certifies cGMP plant/facilities; production test batches have begun; test batches can be employed in Human trials Australia as well as for Tox studies.
Puffer, you've said, "As a near term catalyst you've got potential Dengue approval for orphan status both here and in Europe. That should be forthcoming, possibly within a few weeks (due within 3 mos of 10 Jun in the U.S.). Beyond that I would encourage people to look at the big picture. We could be in or very close to human trials 1 yr hence. Phase I/IIa should only take about 6 weeks... positive results there and $1.00 will be a distant memory. I would also expect higher prices as we approach those trials."
I must say I like the big picture. Nanopatent recently brought to our attention Nanowerk news -- Cancer nanotechnology: Nanoparticles with protein 'passports' evade immune system. Others have alluded to a similar mechanism/passport employed by NNVC in the "human-like cells" or nanomicelles.
Download the "soaring to new highs" video --
-- as mp3(or other attention-getter good choice), trim it down to 30 seconds and associate it with NNVC "new high alert" in your app. When people ask you about the tune/alert, tell them it is related to a company, NNVC, that will make possible for the people to live longer, with a virus worst case scenario...the sniffles! Buy, buy, buy!
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
